Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Tavneos
Synonyms :
avacopan
Class :
Complement Inhibitors
Brand Name :
Tavneos
Synonyms :
avacopan
Class :
Complement Inhibitors
Dosage Forms & StrengthsÂ
CapsuleÂ
10mgÂ
Safety and efficacy are not seen in pediatricsÂ
Refer to the adult dosingÂ
may reduce the therapeutic effect of vaccines
poliovirus vaccine, live, trivalent
may reduce the therapeutic effect of vaccines
poliovirus vaccine inactivated
may reduce the therapeutic effect of vaccines
measles, mumps, rubella, and varicella vaccine, live (Rx)
may reduce the therapeutic effect of vaccines
measles mumps and rubella vaccine, live
may reduce the therapeutic effect of vaccines
may reduce the therapeutic effect of vaccines
smallpox (vaccinia) vaccine, live
may reduce the therapeutic effect of vaccines
may reduce the therapeutic effect of vaccines
may decrease the therapeutic effect when combined with COVID-19 vaccine
respiratory syncytial virus vaccine, adjuvanted
may have a decreased therapeutic effect of influenza virus vaccines
respiratory syncytial virus (RSV) vaccine
may have a decreased therapeutic effect of influenza virus vaccines
may diminish the therapeutic effect of drug
immunosuppressants may diminish the therapeutic effect of vaccines
vaccinia immune globulin intravenous (Rx)
immunosuppressants may diminish the therapeutic effect of vaccines
immunosuppressants may diminish the therapeutic effect of vaccines
immunosuppressants may diminish the therapeutic effect of vaccines
immunosuppressants may diminish the therapeutic effect of vaccines
may decrease the diagnostic effect when combined with coccidioides immitis skin test
may have an increased immunosuppressive effect when combined with denosumab
measles, mumps, rubella, and varicella vaccine, live (Rx)
may decrease the therapeutic effect of immunosuppressants
measles mumps and rubella vaccine, live
may decrease the therapeutic effect of immunosuppressants
may decrease the therapeutic effect of immunosuppressants
smallpox (vaccinia) vaccine, live
may decrease the therapeutic effect of immunosuppressants
may decrease the therapeutic effect of immunosuppressants
may have an increased immunosuppressive effect when combined with leflunomide
may decrease the therapeutic effect when combined with sipuleucel-t
may decrease the therapeutic effect when combined with covid-19 vaccine
may decrease the therapeutic effect when combined with influenza virus vaccines
influenza virus vaccine, h5n1, liveÂ
may decrease the therapeutic effect when combined with influenza virus vaccines
influenza virus vaccine (h5n1), adjuvantedÂ
may decrease the therapeutic effect when combined with influenza virus vaccines
The serum concentration of Avacopan may be decreased by strong CYP3A4 inducers
The serum concentration of Avacopan may be decreased by strong CYP3A4 inducers
The serum concentration of Avacopan may be decreased by strong CYP3A4 inducers
The serum concentration of Avacopan may be decreased by strong CYP3A4 inducers
The serum concentration of Avacopan may be decreased by strong CYP3A4 inducers
may have an increasingly adverse effect when combined with poliovirus vaccine (live/trivalent/oral)
measles, mumps, rubella, and varicella vaccine, live 
may have an increasingly adverse effect when combined with poliovirus vaccine (live/trivalent/oral)
CYP3A strong enhancers of the small intestine may reduce the bioavailability of avacopan
may decrease the serum concentration of CYP3A4 Inducers
may enhance the adverse/toxic effect
poliovirus vaccine, live, trivalent
may enhance the adverse/toxic effect
poliovirus vaccine inactivated
may enhance the adverse/toxic effect
may have an increasingly adverse effect when combined with talimogene laherparepvec
the immunosuppressive effect of immunosuppressants (cytotoxic chemotherapy) may be enhanced by abrocitinib
may have an increased immunosuppressive effect when combined with baricitinib
may have an increasingly adverse effect when combined with BCG products
cladribine: they may increase the immunosuppressive effect of selective immunosuppressants
filgrastim: they may increase the immunosuppressive effect of selective immunosuppressants
nadofaragene firadenovec: they may increase the immunosuppressive effect of selective immunosuppressants
natalizumab: they may increase the immunosuppressive effect of selective immunosuppressants
ritlecitinib: they may increase the immunosuppressive effect of selective immunosuppressants
tacrolimus: they may increase the immunosuppressive effect of selective immunosuppressants
upadacitinib: they may increase the immunosuppressive effect of selective immunosuppressants
respiratory syncytial virus vaccine, adjuvanted
may have an increased adverse/toxic effect when combined with immunosuppressants
respiratory syncytial virus (RSV) vaccine
may have an increased adverse/toxic effect when combined with immunosuppressants
respiratory syncytial virus vaccine, adjuvanted
may diminish the pharmacodynamic antagonistic effect of each other when combined
respiratory syncytial virus (RSV) vaccine
may diminish the pharmacodynamic antagonistic effect of each other when combined
respiratory syncytial virus vaccine, adjuvanted
may diminish the therapeutic effect of vaccines
respiratory syncytial virus (RSV) vaccine
may diminish the therapeutic effect of vaccines
may enhance the concentration of serum when combined with avacopan
may enhance the concentration of serum when combined with avacopan
may enhance the concentration of serum when combined with avacopan
may enhance the concentration of serum when combined with avacopan
may enhance the concentration of serum when combined with avacopan
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
When avacopan is used together with fluconazole, this leads to reduction in the avacopan metabolism
When mometasone furoate is used together with avacopan, this leads to enhanced risk or seriousness of adverse outcomes
when combined with danoprevir, the metabolism of avacopan can be reduced
the risk or intensity of negative effects can be heightened when filgotinib is combined with avacopan
when both drugs are combined, there may be a reduced metabolism of paclitaxel 
may decrease the therapeutic effect when combined with pneumococcal vaccines
may decrease the therapeutic effect when combined with pidotimod
may decrease the therapeutic effect when combined with brincidofovir
antithymocyte globulin equineÂ
may increase the immunosuppressive effect of immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
inebilizumab: they may increase the immunosuppressive effect of selective immunosuppressants
ocrelizumab: they may increase the immunosuppressive effect of selective immunosuppressants
ofatumumab: they may increase the immunosuppressive effect of selective immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
the risk of adverse effects can be increased
When avacopan is used together with lomitapide, this leads to enhanced concentration serum of lomitapide
Actions and Spectrum:Â
Actions:Â
Spectrum:Â
avacopan has primarily been studied and developed for treating certain autoimmune diseases characterized by excessive inflammation and immune system dysregulation. It shows promising treatment of:Â
Frequency definedÂ
>10%Â
Nausea (23.5%)Â
Headache (20.5%)Â
Vomiting (15.1%)Â
Hepatic-related adverse reactions (13.3%)Â
Hypertension (18.1%)Â
Diarrhea (15.1%)Â
Rash (11.4%)Â
Fatigue (10.2%)Â Â
1-10%Â
Blood creatinine increased (6%)Â
Paresthesia (5.4%)Â
Upper abdominal pain (6.6%)Â
Dizziness (6.6%)Â
Elevated creatine phosphokinase (3.6%)Â
Angioedema (1.2%)Â
Black Box Warning:Â
None Â
Contraindication/Caution:Â
ContraindicationsÂ
CautionsÂ
Pregnancy consideration:Â Â
No data is available regarding the administration of the drug during pregnancy.Â
Breastfeeding warnings:Â Â
No data is available regarding the excretion of drug in breast milk.Â
Pregnancy category:Â
Category A: well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester.Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: No data is available for the drug under this category.Â
Pharmacology:Â
avacopan is a selective antagonist of the C5a receptor, also known as the C5aR or CD88 receptor. C5a is a pro-inflammatory molecule involved in activating and recruiting immune cells, particularly neutrophils, during the inflammatory response. By blocking the C5a receptor, avacopan inhibits the binding of C5a and prevents its signaling, leading to a reduction in neutrophil activation and migration to the site of inflammation. This helps modulate the immune response and dampen excessive inflammation in certain autoimmune and inflammatory conditions.Â
Pharmacodynamics:Â
The pharmacodynamics of avacopan involves its effects on the immune system and the modulation of inflammation. By blocking the C5a receptor, avacopan prevents the binding of C5a and subsequent signaling, leading to reduced activation and migration of neutrophils. This helps attenuate the immune response, decrease inflammation, and alleviate symptoms associated with certain autoimmune and inflammatory conditions.Â
Pharmacokinetics:Â
AbsorptionÂ
The peak plasma concentration is 349ng/mlÂ
The area under the curve is 3466ngâ‹…h/mLÂ
DistributionÂ
Protein-bound is more than 99%Â
The volume of distribution is 345LÂ Â
MetabolismÂ
avacopan undergoes metabolism primarily in the liver. It is metabolized by cytochrome P450 enzymes, particularly CYP3A4, into less pharmacologically active metabolites.Â
Elimination and ExcretionÂ
The elimination of avacopan occurs mainly through hepatic metabolism, with the metabolites being excreted in the feces. The exact clearance and elimination half-life of avacopan may vary among individuals.Â
Administration:Â
avacopan is administered orally, which means it is taken by mouth. It is available in tablets or capsules that should be swallowed whole with water or as the healthcare provider instructs. avacopan should not be chewed, crushed, or divided unless otherwise specified. The recommended dosage of avacopan may vary depending on the specific condition being treated and individual patient factors.Â
Patient information leafletÂ
Generic Name: avacopanÂ
Pronounced: A-va-KOE-panÂ
Why do we use avacopan?Â
avacopan is used for the treatment of ANCA-associated vasculitis (AAV), which includes microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA, formerly known as Wegener’s granulomatosis).Â
avacopan is specifically indicated for the treatment of AAV. It is used in adults with AAV to reduce disease activity, induce and maintain remission, and prevent relapses.Â
avacopan is typically used in combination with standard immunosuppressive therapy for AAV. This may include glucocorticoids (such as prednisone) and other immunosuppressive medications like rituximab or cyclophosphamide. avacopan is often initiated concurrently with immunosuppressive therapy and continued as a maintenance therapy after remission induction.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
